European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure

Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to devel...

Full description

Saved in:

Bibliographic Details
Published in	Journal of headache and pain Vol. 23; no. 1; pp. 133 - 10
Main Authors	Sacco, Simona, Lampl, Christian, Amin, Faisal Mohammad, Braschinsky, Mark, Deligianni, Christina, Uludüz, Derya, Versijpt, Jan, Ducros, Anne, Gil-Gouveia, Raquel, Katsarava, Zaza, Martelletti, Paolo, Ornello, Raffaele, Raffaelli, Bianca, Boucherie, Deirdre M., Pozo-Rosich, Patricia, Sanchez-del-Rio, Margarita, Sinclair, Alexandra, Maassen van den Brink, Antoinette, Reuter, Uwe
Format	Journal Article
Language	English
Published	Milan Springer Milan 12.10.2022 Springer Nature B.V SpringerOpen BMC
Subjects	Attack Clinical medicine Consensus Consensus Article Ditan Drug resistance Gepant Headache Headaches Internal Medicine Life Sciences Literature reviews Medication Medicine Medicine & Public Health Migraine Neurobiology Neurology Neurons and Cognition Pain management Pain Medicine Patients Pharmaceutical sciences Triptan Well being Headache Ditan Migraine NSAIDs Attack Triptan Gepant
Online Access	Get full text
ISSN	1129-2369 1129-2377 1129-2377
DOI	10.1186/s10194-022-01502-z

Cover

Loading…

Abstract	Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder. Main body The Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient’s well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory , in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics. Conclusions The novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care.
AbstractList	Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder. Main body The Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient’s well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory , in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics. Conclusions The novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care. Abstract Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder. Main body The Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient’s well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory, in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics. Conclusions The novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care. BackgroundTriptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder.Main bodyThe Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient’s well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory, in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics.ConclusionsThe novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care. Background. Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder. Main body The Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient’s well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory , in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics. Conclusions. The novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care. Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder.BACKGROUNDTriptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder.The Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient's well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory, in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics.MAIN BODYThe Consensus process included a preliminary literature review, a Delphi round and a subsequent open discussion. According to the Consensus Panel, effective treatment of a migraine attack is to be defined on patient well-being featured by a) improvement of headache, b) relief of non-pain symptoms and c) absence of adverse events. An attack is considered effectively treated if patient's well-being, as defined above, is restored within 2 hours and for at least 24 hours. An individual with migraine is considered as triptan-responder when the given triptan leads to effective acute attack treatment in at least three out of four migraine attacks. On the other hand, an individual with migraine is considered triptan non-responder in the presence of failure of a single triptan (not matching the definition of triptan-responder). The Consensus Panel defined an individual with migraine as triptan-resistant in the presence of failure of at least 2 triptans; triptan refractory, in the presence of failure to at least 3 triptans, including subcutaneous formulation; triptan ineligibile in the presence of an acknowledged contraindication to triptan use, as specified in the summary of product characteristics.The novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care.CONCLUSIONSThe novel definitions can be useful in clinical practice for the assessment of acute attack treatments patients with migraine. They may be helpful in identifying people not responding to triptans and in need for novel acute migraine treatments. The definitions will also be of help in standardizing research on migraine acute care.
ArticleNumber	133
Author	Ducros, Anne Martelletti, Paolo Sinclair, Alexandra Sacco, Simona Maassen van den Brink, Antoinette Sanchez-del-Rio, Margarita Versijpt, Jan Uludüz, Derya Raffaelli, Bianca Lampl, Christian Boucherie, Deirdre M. Reuter, Uwe Gil-Gouveia, Raquel Deligianni, Christina Pozo-Rosich, Patricia Braschinsky, Mark Ornello, Raffaele Katsarava, Zaza Amin, Faisal Mohammad
Author_xml	– sequence: 1 givenname: Simona orcidid: 0000-0003-0651-1939 surname: Sacco fullname: Sacco, Simona email: simona.sacco@univaq.it organization: Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila – sequence: 2 givenname: Christian orcidid: 0000-0003-1756-1181 surname: Lampl fullname: Lampl, Christian organization: Department of Neurology, Headache Medical Center at the Konventhospital BHB Linz – sequence: 3 givenname: Faisal Mohammad orcidid: 0000-0003-3803-3599 surname: Amin fullname: Amin, Faisal Mohammad organization: Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Department of Neurorehabilitation/Traumatic Brain Injury, Rigshospitalet, University of Copenhagen – sequence: 4 givenname: Mark orcidid: 0000-0002-3457-0242 surname: Braschinsky fullname: Braschinsky, Mark organization: Department of Neurology, Institute of Clinical Medicine, University of Tartu; Headache Clinic, Department of Neurology, Tartu University Hospital – sequence: 5 givenname: Christina orcidid: 0000-0002-6208-1059 surname: Deligianni fullname: Deligianni, Christina organization: Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen – sequence: 6 givenname: Derya orcidid: 0000-0002-0862-1958 surname: Uludüz fullname: Uludüz, Derya organization: Department of Neurology Istanbul Cerrahpasa Medical Faculty – sequence: 7 givenname: Jan orcidid: 0000-0002-8710-5715 surname: Versijpt fullname: Versijpt, Jan organization: Department of Neurology, Vrije Universiteit Brussel (VUB), Universitair – sequence: 8 givenname: Anne orcidid: 0000-0001-5560-5013 surname: Ducros fullname: Ducros, Anne organization: Neurology Department, CHU de Montpellier Charles Coulomb Laboratory, Montpellier University – sequence: 9 givenname: Raquel orcidid: 0000-0002-4256-4256 surname: Gil-Gouveia fullname: Gil-Gouveia, Raquel organization: Neurology Department, Hospital da Luz Headache Center, Hospital da Luz, Center for Interdisciplinary Research in Health, Universidade Católica Portuguesa – sequence: 10 givenname: Zaza orcidid: 0000-0002-9932-1159 surname: Katsarava fullname: Katsarava, Zaza organization: Christian Hospital, University of Duisburg-Essen – sequence: 11 givenname: Paolo orcidid: 0000-0002-6556-4128 surname: Martelletti fullname: Martelletti, Paolo organization: Department of Clinical and Molecular Medicine, Sapienza University – sequence: 12 givenname: Raffaele orcidid: 0000-0001-9501-4031 surname: Ornello fullname: Ornello, Raffaele organization: Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila – sequence: 13 givenname: Bianca orcidid: 0000-0001-9758-1494 surname: Raffaelli fullname: Raffaelli, Bianca organization: Department of Neurology, Charité Universitätsmedizin Berlin – sequence: 14 givenname: Deirdre M. surname: Boucherie fullname: Boucherie, Deirdre M. organization: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center – sequence: 15 givenname: Patricia orcidid: 0000-0003-0796-4702 surname: Pozo-Rosich fullname: Pozo-Rosich, Patricia organization: Headache Unit, Neurology Department, Vall d’Hebron University Hospital, Department of Medicine, Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Universitat Autònoma de Barcelona – sequence: 16 givenname: Margarita orcidid: 0000-0001-7724-2890 surname: Sanchez-del-Rio fullname: Sanchez-del-Rio, Margarita organization: Department of Neurology, Clinica Universidad de Navarra – sequence: 17 givenname: Alexandra orcidid: 0000-0003-2777-5132 surname: Sinclair fullname: Sinclair, Alexandra organization: Institute of Metabolism and Sytems Research, University of Birmingham, Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital – sequence: 18 givenname: Antoinette orcidid: 0000-0001-7176-126X surname: Maassen van den Brink fullname: Maassen van den Brink, Antoinette organization: Department of Internal Medicine, Erasmus MC Medical Center – sequence: 19 givenname: Uwe orcidid: 0000-0002-8527-0725 surname: Reuter fullname: Reuter, Uwe organization: Department of Neurology, Charité Universitätsmedizin Berlin, Universitätsmedizin Greifswald
BackLink	https://hal.umontpellier.fr/hal-04485835$$DView record in HAL
BookMark	eNp9kkFv2yAUx62pk9Z2-wI7WdqlPXgDDNi-TKqqZKkUaZftjDA8EjIHMsCR1tu--XDcbWoOPQGP3___3oN3VVw476Ao3mP0EeOWf4oY4Y5WiJAKYYZI9fiquMSYdBWpm-bi3553b4qrGHcIEVS37LL4vRiDP4B05QqklmoL5RI0BJmsd-XNYrW8LZV3EVwcY5lDKRMajHX2RHhTgjGgkj1CmQLItAeXprAs93YTpHVQypSk-lFKp6eLFOwh5YRG2mEM8LZ4beQQ4d3Tel18Xy6-3a-q9dcvD_d360qxFqUKoK2ZqTuDOe1MPmnGeM9pq5tWSdJI4KYBRoxEPdWoxkS3ijY8N0O57nF9XTzMvtrLnTgEu5fhl_DSilPAh42QIVk1gDAEcN2ppjO0oZz0fSNrggDRFnW4lpC9Ps9eh7Hfg1a55SCHZ6bPb5zdio0_io4xhnmdDW5ng-2ZbHW3FlMMUdqy3PFxKvzmKVnwP0eISextVDAM0oEfoyANoRPK24x-OEN3fgwuP-uJQg3jmGWqnSkVfIwBjFA2nT4812oHgZGYhkrMQyXyUInTUInHLCVn0r_FvyiqZ1HMsNtA-F_VC6o_bmbing
CitedBy_id	crossref_primary_10_1080_14737175_2024_2342446 crossref_primary_10_1177_03331024251318016 crossref_primary_10_1007_s40122_023_00538_6 crossref_primary_10_1080_13696998_2024_2340932 crossref_primary_10_1186_s10194_024_01766_7 crossref_primary_10_1007_s40122_025_00705_x crossref_primary_10_1186_s12883_024_03600_8 crossref_primary_10_1080_14656566_2023_2201375 crossref_primary_10_3390_brainsci14090948 crossref_primary_10_1177_03331024251325526 crossref_primary_10_14412_2074_2711_2024_2_76_86 crossref_primary_10_3390_ijerph192214696 crossref_primary_10_1111_head_14854 crossref_primary_10_1186_s10194_024_01924_x crossref_primary_10_14412_2074_2711_2024_4_41_48 crossref_primary_10_1097_WCO_0000000000001153 crossref_primary_10_3390_healthcare13020164 crossref_primary_10_1007_s11916_024_01213_x crossref_primary_10_1186_s10194_024_01904_1 crossref_primary_10_1212_WNL_0000000000207964 crossref_primary_10_1016_j_pmn_2024_12_006 crossref_primary_10_1186_s10194_024_01889_x crossref_primary_10_14412_2074_2711_2023_2_126_133 crossref_primary_10_1177_00185787241267738 crossref_primary_10_1007_s10072_024_07493_w crossref_primary_10_1080_14728214_2023_2288334 crossref_primary_10_1016_j_ebiom_2023_104943 crossref_primary_10_3390_women3030029 crossref_primary_10_1016_j_neurol_2024_09_008 crossref_primary_10_1177_25158163241235130 crossref_primary_10_1186_s10194_023_01676_0 crossref_primary_10_3389_fneur_2024_1402569 crossref_primary_10_31083_j_jin2205126 crossref_primary_10_1177_03331024241278911 crossref_primary_10_1186_s10194_024_01873_5 crossref_primary_10_1177_03331024241252666 crossref_primary_10_14412_2074_2711_2023_5_109_116 crossref_primary_10_1007_s40120_023_00576_4 crossref_primary_10_1007_s00415_023_11706_1 crossref_primary_10_1007_s42399_022_01369_w crossref_primary_10_14412_2074_2711_2024_5_60_68 crossref_primary_10_1186_s10194_024_01913_0 crossref_primary_10_1371_journal_pone_0300816 crossref_primary_10_1007_s40263_023_00988_8 crossref_primary_10_1016_j_pharmthera_2023_108523 crossref_primary_10_4081_cc_2024_15770
Cites_doi	10.1046/j.1526-4610.1998.3804288.x 10.1046/j.1526-4610.2003.03073.x 10.1111/j.1526-4610.2009.01523.x 10.1016/j.pharmthera.2020.107528 10.1097/j.pain.0000000000001801 10.1016/j.jclinepi.2021.03.001 10.1016/j.jbi.2008.08.010 10.1007/s00228-007-0443-9 10.1046/j.1468-2982.1998.1805273.x 10.1046/j.1468-2982.2002.00404.x 10.1046/j.1468-2982.2000.00091.x 10.1186/s10194-018-0899-2 10.1111/head.13327 10.2165/00023210-200317110-00005 10.1517/14656566.2013.806487 10.1093/brain/awz134 10.1177/0333102413480756 10.1212/WNL.0000000000011216 10.1007/s10194-010-0258-4 10.1046/j.1526-4610.2002.02025.x 10.1111/head.13530 10.1185/03007999909116497 10.1016/j.pain.2005.03.008 10.1111/j.1526-4610.2007.00792.x 10.1016/S0140-6736(19)31606-X 10.1517/13543784.10.10.1831 10.1111/head.13105 10.2165/00003495-200060060-00003 10.1111/head.13708 10.1111/j.1468-2982.2005.01010.x 10.1007/s00228-002-0461-6 10.1111/j.1526-4610.2004.04104.x 10.1001/jama.2019.16711 10.1177/0333102413500726 10.1002/ana.410330109 10.1212/WNL.55.10.1511 10.3390/jcm10071429
ContentType	Journal Article
Copyright	The Author(s) 2022 The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). Attribution
Copyright_xml	– notice: The Author(s) 2022 – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). – notice: Attribution
DBID	C6C AAYXX CITATION 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M1P M2M NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 1XC VOOES 5PM DOA
DOI	10.1186/s10194-022-01502-z
DatabaseName	Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Proquest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1129-2377
EndPage	10
ExternalDocumentID	oai_doaj_org_article_f2e139c79f47462bb7a320e0480913ae PMC9555163 oai_HAL_hal_04485835v1 10_1186_s10194_022_01502_z
GroupedDBID	--- -5E -5G -A0 -BR -Y2 -~C .86 0R~ 123 1SB 29K 2P1 2VQ 36B 3V. 4.4 40G 53G 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ AAFWJ AAIAL AAJSJ AAKDD AAKKN AANXM AAWTL AAYZH ABEEZ ABIVO ABMNI ABTEG ABUWG ACACY ACGFS ACOMO ACPRK ACULB ADBBV ADINQ ADKPE ADQRH ADRAZ ADRFC AENEX AFBBN AFGXO AFKRA AFLOW AFPKN AGJBK AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS AZQEC BA0 BAPOH BAWUL BCNDV BENPR BFQNJ BGNMA BKEYQ BMC BPHCQ BVXVI C24 C6C CAG CCPQU COF CS3 CSCUP D-I DIK DL5 DU5 DWQXO EBLON EBS EJD EMB EMOBN EX3 F5P FYUFA GNUQQ GROUPED_DOAJ GXS H13 HF~ HG6 HMCUK HYE HZ~ I09 IHE IXC IXE IZQ I~X KDC KOV KPH KQ8 LAS M1P M2M M48 M4Y M~E NAPCQ NB0 NU0 O9- OAM OK1 PGMZT PIMPY PQQKQ PROAC PSQYO PSYQQ PZZ Q2X RNS ROL RPM RPX RRX RSV S1Z S27 SDH SMD SOJ SV3 T13 TSK U2A UKHRP VC2 WJK WOW Z7U Z82 Z87 ~KM AASML AAYXX CITATION PHGZM PHGZT 7TK 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 1XC VOOES 5PM ADUKV PUEGO
ID	FETCH-LOGICAL-c580t-ee835f39f1649fee8d556b648d78ca27ae6f7e52fa0b4d0312d8c476ede46db13
IEDL.DBID	M48
ISSN	1129-2369 1129-2377
IngestDate	Wed Aug 27 00:52:38 EDT 2025 Thu Aug 21 18:39:23 EDT 2025 Fri Jul 18 06:20:53 EDT 2025 Thu Jul 10 22:28:48 EDT 2025 Fri Jul 25 09:10:05 EDT 2025 Tue Jul 01 02:56:53 EDT 2025 Thu Apr 24 22:58:57 EDT 2025 Fri Feb 21 02:45:15 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Headache Ditan Migraine NSAIDs Attack Triptan Gepant
Language	English
License	Attribution: http://creativecommons.org/licenses/by Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c580t-ee835f39f1649fee8d556b648d78ca27ae6f7e52fa0b4d0312d8c476ede46db13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0002-9932-1159 0000-0002-8710-5715 0000-0002-4256-4256 0000-0003-0796-4702 0000-0002-6556-4128 0000-0002-3457-0242 0000-0003-1756-1181 0000-0001-9758-1494 0000-0001-5560-5013 0000-0001-9501-4031 0000-0001-7176-126X 0000-0003-0651-1939 0000-0002-8527-0725 0000-0003-3803-3599 0000-0003-2777-5132 0000-0002-6208-1059 0000-0002-0862-1958 0000-0001-7724-2890
OpenAccessLink	http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s10194-022-01502-z
PQID	2724075615
PQPubID	43392
PageCount	10
ParticipantIDs	doaj_primary_oai_doaj_org_article_f2e139c79f47462bb7a320e0480913ae pubmedcentral_primary_oai_pubmedcentral_nih_gov_9555163 hal_primary_oai_HAL_hal_04485835v1 proquest_miscellaneous_2724583568 proquest_journals_2724075615 crossref_citationtrail_10_1186_s10194_022_01502_z crossref_primary_10_1186_s10194_022_01502_z springer_journals_10_1186_s10194_022_01502_z
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2022-10-12
PublicationDateYYYYMMDD	2022-10-12
PublicationDate_xml	– month: 10 year: 2022 text: 2022-10-12 day: 12
PublicationDecade	2020
PublicationPlace	Milan
PublicationPlace_xml	– name: Milan – name: Milano
PublicationSubtitle	Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache"
PublicationTitle	Journal of headache and pain
PublicationTitleAbbrev	J Headache Pain
PublicationYear	2022
Publisher	Springer Milan Springer Nature B.V SpringerOpen BMC
Publisher_xml	– name: Springer Milan – name: Springer Nature B.V – name: SpringerOpen – name: BMC
References	Dahlof, Lipton, McCarroll, Kramer, Lines, Ferrari (CR27) 2000; 55 Ahn, Basbaum (CR5) 2005; 115 Steiner, Jensen, Katsarava, Linde, MacGregor, Osipova (CR7) 2019; 20 Dodick, Tepper, Friedman, Gelfand, Kellerman, Schmidt (CR36) 2018; 58 Ramirez Rosas, Labruijere, Villalon, Maassen Vandenbrink (CR3) 2013; 14 CR33 van Casteren, Kurth, Danser, Terwindt, MaassenVanDenBrink (CR14) 2021; 96 Ferrari, Tiraferri, Neri, Sternieri (CR19) 2011; 12 Ashford, Salonen, Saiers, Woessner (CR25) 1998; 18 Pascual, Falk, Piessens, Prusinski, Docekal, Robert (CR30) 2000; 20 Labastida-Ramirez, Rubio-Beltran, Haanes, Chan, Garrelds, Johnson (CR2) 2020; 161 Dowson, Charlesworth, Purdy, Becker, Boes-Hansen, Farkkila (CR28) 2003; 17 Goadsby, Wietecha, Dennehy, Kuca, Case, Aurora (CR37) 2019; 142 Ferrari, Pinetti, Bertolini, Coccia, Sternieri (CR10) 2008; 64 Page, McKenzie, Bossuyt, Boutron, Hoffmann, Mulrow (CR20) 2021; 134 Cady, Vause, Ho, Bigal, Durham (CR18) 2009; 49 Harris, Taylor, Thielke, Payne, Gonzalez, Conde (CR22) 2009; 42 Dahlof (CR13) 2006; 26 Dahlof, Dodick, Dowson, Pascual (CR26) 2002; 42 Tfelt-Hansen, De Vries, Saxena (CR4) 2000; 60 Almas, Tepper, Landy, Schweizer, Ramos (CR24) 2014; 34 Ferrari, Goadsby, Roon, Lipton (CR6) 2002; 22 Viana, Genazzani, Terrazzino, Nappi, Goadsby (CR9) 2013; 33 Tuchman, Edvinsson, Geraud, Korczyn, Mauskop, Pfaffenrath (CR32) 1999; 15 Goadsby, Edvinsson (CR17) 1993; 33 Mehrotra, Vanmolkot, Frants, van den Maagdenberg, Ferrari, MaassenVanDenBrink (CR12) 2007; 47 Maassen Van Den Brink, Saxena (CR1) 2004; 44 Diener, Limmroth (CR8) 2001; 10 Dalkey, Helmer-Hirschberg (CR21) 1962 Geraud, Keywood, Senard (CR16) 2003; 43 McGinley, Buse, Shulman, Wirth, Hugentobler, Lipton (CR29) 2019; 59 Silberstein, Winner, McAllister, Tepper, Halker, Mahmoud (CR31) 2017; 57 Yates, Tateno, Nairn, Ikegami, Dane, Kemp (CR15) 2002; 58 Croop, Goadsby, Stock, Conway, Forshaw, Stock (CR35) 2019; 394 MaassenVanDenBrink, Vergouwe, Ophoff, Saxena, Ferrari, Frants (CR11) 1998; 38 de Vries, Villalon, MaassenVanDenBrink (CR34) 2020; 211 Lipton, Dodick, Ailani, Lu, Finnegan, Szegedi (CR38) 2019; 322 Munjal, Singh, Reed, Fanning, Schwedt, Dodick (CR23) 2020; 60 MB Ramirez Rosas (1502_CR3) 2013; 14 RK Cady (1502_CR18) 2009; 49 T de Vries (1502_CR34) 2020; 211 CG Dahlof (1502_CR13) 2006; 26 M Tuchman (1502_CR32) 1999; 15 AH Ahn (1502_CR5) 2005; 115 G Geraud (1502_CR16) 2003; 43 1502_CR33 A Labastida-Ramirez (1502_CR2) 2020; 161 CG Dahlof (1502_CR27) 2000; 55 S Silberstein (1502_CR31) 2017; 57 E Ashford (1502_CR25) 1998; 18 NC Dalkey (1502_CR21) 1962 RA Yates (1502_CR15) 2002; 58 JS McGinley (1502_CR29) 2019; 59 PJ Goadsby (1502_CR17) 1993; 33 MD Ferrari (1502_CR6) 2002; 22 S Mehrotra (1502_CR12) 2007; 47 TJ Steiner (1502_CR7) 2019; 20 CG Dahlof (1502_CR26) 2002; 42 A Ferrari (1502_CR10) 2008; 64 PJ Goadsby (1502_CR37) 2019; 142 MJ Page (1502_CR20) 2021; 134 DW Dodick (1502_CR36) 2018; 58 J Pascual (1502_CR30) 2000; 20 DS van Casteren (1502_CR14) 2021; 96 P Tfelt-Hansen (1502_CR4) 2000; 60 A Maassen Van Den Brink (1502_CR1) 2004; 44 M Viana (1502_CR9) 2013; 33 R Croop (1502_CR35) 2019; 394 HC Diener (1502_CR8) 2001; 10 RB Lipton (1502_CR38) 2019; 322 A MaassenVanDenBrink (1502_CR11) 1998; 38 PA Harris (1502_CR22) 2009; 42 S Munjal (1502_CR23) 2020; 60 M Almas (1502_CR24) 2014; 34 AJ Dowson (1502_CR28) 2003; 17 A Ferrari (1502_CR19) 2011; 12
References_xml	– volume: 38 start-page: 288 issue: 4 year: 1998 end-page: 291 ident: CR11 article-title: 5-HT1B receptor polymorphism and clinical response to sumatriptan publication-title: Headache. doi: 10.1046/j.1526-4610.1998.3804288.x – volume: 43 start-page: 376 issue: 4 year: 2003 end-page: 388 ident: CR16 article-title: Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans publication-title: Headache. doi: 10.1046/j.1526-4610.2003.03073.x – volume: 49 start-page: 1258 issue: 9 year: 2009 end-page: 1266 ident: CR18 article-title: Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan publication-title: Headache. doi: 10.1111/j.1526-4610.2009.01523.x – volume: 211 start-page: 107528 year: 2020 ident: CR34 article-title: Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2020.107528 – volume: 161 start-page: 1092 issue: 5 year: 2020 end-page: 1099 ident: CR2 article-title: Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system publication-title: Pain. doi: 10.1097/j.pain.0000000000001801 – volume: 134 start-page: 178 year: 2021 end-page: 189 ident: CR20 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2021.03.001 – volume: 42 start-page: 377 issue: 2 year: 2009 end-page: 381 ident: CR22 article-title: Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support publication-title: J Biomed Inform doi: 10.1016/j.jbi.2008.08.010 – volume: 64 start-page: 489 issue: 5 year: 2008 end-page: 495 ident: CR10 article-title: Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-007-0443-9 – ident: CR33 – volume: 18 start-page: 273 issue: 5 year: 1998 end-page: 277 ident: CR25 article-title: Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.1998.1805273.x – volume: 22 start-page: 633 issue: 8 year: 2002 end-page: 658 ident: CR6 article-title: Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.2002.00404.x – volume: 20 start-page: 588 issue: 6 year: 2000 end-page: 596 ident: CR30 article-title: Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.2000.00091.x – volume: 20 start-page: 57 issue: 1 year: 2019 ident: CR7 article-title: Aids to management of headache disorders in primary care (2nd edition) : on behalf of the european headache federation and lifting the burden: the global campaign against headache publication-title: J Headache Pain. doi: 10.1186/s10194-018-0899-2 – year: 1962 ident: CR21 publication-title: An experimental application of the Delphi method to the use of experts – volume: 58 start-page: 986 issue: 7 year: 2018 end-page: 992 ident: CR36 article-title: Use of Most bothersome symptom as a Coprimary endpoint in migraine clinical trials: a post-hoc analysis of the pivotal ZOTRIP randomized, Controlled Trial publication-title: Headache doi: 10.1111/head.13327 – volume: 17 start-page: 839 issue: 11 year: 2003 end-page: 851 ident: CR28 article-title: Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial publication-title: CNS Drugs doi: 10.2165/00023210-200317110-00005 – volume: 14 start-page: 1599 issue: 12 year: 2013 end-page: 1610 ident: CR3 article-title: Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2013.806487 – volume: 142 start-page: 1894 issue: 7 year: 2019 end-page: 1904 ident: CR37 article-title: Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine publication-title: Brain. doi: 10.1093/brain/awz134 – volume: 33 start-page: 891 issue: 11 year: 2013 end-page: 896 ident: CR9 article-title: Triptan nonresponders: do they exist and who are they? publication-title: Cephalalgia. doi: 10.1177/0333102413480756 – volume: 96 start-page: 162 issue: 4 year: 2021 end-page: 170 ident: CR14 article-title: Sex differences in response to Triptans: a systematic review and Meta-analysis publication-title: Neurology. doi: 10.1212/WNL.0000000000011216 – volume: 12 start-page: 5 issue: 1 year: 2011 end-page: 12 ident: CR19 article-title: Why pharmacokinetic differences among oral triptans have little clinical importance: a comment publication-title: J Headache Pain doi: 10.1007/s10194-010-0258-4 – volume: 42 start-page: 99 issue: 2 year: 2002 end-page: 113 ident: CR26 article-title: How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials publication-title: Headache. doi: 10.1046/j.1526-4610.2002.02025.x – volume: 59 start-page: 1002 issue: 7 year: 2019 end-page: 1013 ident: CR29 article-title: Evaluating mean level and within-person consistency in migraine pain intensity and migraine-related disability for AVP-825 vs Oral Sumatriptan: results from the COMPASS study, A Randomized Trial publication-title: Headache doi: 10.1111/head.13530 – volume: 15 start-page: 272 issue: 4 year: 1999 end-page: 281 ident: CR32 article-title: Zolmitriptan provides consistent migraine relief when used in the long-term publication-title: Curr Med Res Opin doi: 10.1185/03007999909116497 – volume: 115 start-page: 1 issue: 1–2 year: 2005 end-page: 4 ident: CR5 article-title: Where do triptans act in the treatment of migraine? publication-title: Pain. doi: 10.1016/j.pain.2005.03.008 – volume: 47 start-page: 711 issue: 5 year: 2007 end-page: 716 ident: CR12 article-title: The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan publication-title: Headache. doi: 10.1111/j.1526-4610.2007.00792.x – volume: 394 start-page: 737 issue: 10200 year: 2019 end-page: 745 ident: CR35 article-title: Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial publication-title: Lancet. doi: 10.1016/S0140-6736(19)31606-X – volume: 10 start-page: 1831 issue: 10 year: 2001 end-page: 1845 ident: CR8 article-title: Advances in pharmacological treatment of migraine publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.10.10.1831 – volume: 57 start-page: 862 issue: 6 year: 2017 end-page: 876 ident: CR31 article-title: Early onset of efficacy and consistency of response across multiple migraine attacks from the randomized COMPASS study: AVP-825 breath powered((R)) exhalation delivery system (Sumatriptan nasal powder) vs Oral Sumatriptan publication-title: Headache. doi: 10.1111/head.13105 – volume: 60 start-page: 1259 issue: 6 year: 2000 end-page: 1287 ident: CR4 article-title: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy publication-title: Drugs. doi: 10.2165/00003495-200060060-00003 – volume: 60 start-page: 416 issue: 2 year: 2020 end-page: 429 ident: CR23 article-title: Most bothersome symptom in persons with migraine: results from the migraine in America symptoms and treatment (MAST) study publication-title: Headache. doi: 10.1111/head.13708 – volume: 26 start-page: 98 issue: 2 year: 2006 end-page: 106 ident: CR13 article-title: Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials publication-title: Cephalalgia. doi: 10.1111/j.1468-2982.2005.01010.x – volume: 58 start-page: 247 issue: 4 year: 2002 end-page: 252 ident: CR15 article-title: The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-002-0461-6 – volume: 44 start-page: S13 issue: Suppl 1 year: 2004 end-page: S19 ident: CR1 article-title: Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data publication-title: Headache. doi: 10.1111/j.1526-4610.2004.04104.x – volume: 322 start-page: 1887 issue: 19 year: 2019 end-page: 1898 ident: CR38 article-title: Effect of Ubrogepant vs placebo on pain and the Most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial publication-title: JAMA. doi: 10.1001/jama.2019.16711 – volume: 34 start-page: 126 issue: 2 year: 2014 end-page: 135 ident: CR24 article-title: Consistency of eletriptan in treating migraine: results of a randomized, within-patient multiple-dose study publication-title: Cephalalgia. doi: 10.1177/0333102413500726 – volume: 33 start-page: 48 issue: 1 year: 1993 end-page: 56 ident: CR17 article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats publication-title: Ann Neurol doi: 10.1002/ana.410330109 – volume: 55 start-page: 1511 issue: 10 year: 2000 end-page: 1516 ident: CR27 article-title: Within-patient consistency of response of rizatriptan for treating migraine publication-title: Neurology. doi: 10.1212/WNL.55.10.1511 – volume: 14 start-page: 1599 issue: 12 year: 2013 ident: 1502_CR3 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2013.806487 – volume: 115 start-page: 1 issue: 1–2 year: 2005 ident: 1502_CR5 publication-title: Pain. doi: 10.1016/j.pain.2005.03.008 – volume: 33 start-page: 891 issue: 11 year: 2013 ident: 1502_CR9 publication-title: Cephalalgia. doi: 10.1177/0333102413480756 – volume-title: An experimental application of the Delphi method to the use of experts year: 1962 ident: 1502_CR21 – volume: 20 start-page: 588 issue: 6 year: 2000 ident: 1502_CR30 publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.2000.00091.x – volume: 96 start-page: 162 issue: 4 year: 2021 ident: 1502_CR14 publication-title: Neurology. doi: 10.1212/WNL.0000000000011216 – volume: 10 start-page: 1831 issue: 10 year: 2001 ident: 1502_CR8 publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.10.10.1831 – volume: 161 start-page: 1092 issue: 5 year: 2020 ident: 1502_CR2 publication-title: Pain. doi: 10.1097/j.pain.0000000000001801 – volume: 64 start-page: 489 issue: 5 year: 2008 ident: 1502_CR10 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-007-0443-9 – volume: 47 start-page: 711 issue: 5 year: 2007 ident: 1502_CR12 publication-title: Headache. doi: 10.1111/j.1526-4610.2007.00792.x – volume: 44 start-page: S13 issue: Suppl 1 year: 2004 ident: 1502_CR1 publication-title: Headache. doi: 10.1111/j.1526-4610.2004.04104.x – volume: 57 start-page: 862 issue: 6 year: 2017 ident: 1502_CR31 publication-title: Headache. doi: 10.1111/head.13105 – volume: 17 start-page: 839 issue: 11 year: 2003 ident: 1502_CR28 publication-title: CNS Drugs doi: 10.2165/00023210-200317110-00005 – volume: 60 start-page: 1259 issue: 6 year: 2000 ident: 1502_CR4 publication-title: Drugs. doi: 10.2165/00003495-200060060-00003 – volume: 60 start-page: 416 issue: 2 year: 2020 ident: 1502_CR23 publication-title: Headache. doi: 10.1111/head.13708 – volume: 33 start-page: 48 issue: 1 year: 1993 ident: 1502_CR17 publication-title: Ann Neurol doi: 10.1002/ana.410330109 – volume: 22 start-page: 633 issue: 8 year: 2002 ident: 1502_CR6 publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.2002.00404.x – volume: 42 start-page: 99 issue: 2 year: 2002 ident: 1502_CR26 publication-title: Headache. doi: 10.1046/j.1526-4610.2002.02025.x – volume: 394 start-page: 737 issue: 10200 year: 2019 ident: 1502_CR35 publication-title: Lancet. doi: 10.1016/S0140-6736(19)31606-X – volume: 211 start-page: 107528 year: 2020 ident: 1502_CR34 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2020.107528 – volume: 15 start-page: 272 issue: 4 year: 1999 ident: 1502_CR32 publication-title: Curr Med Res Opin doi: 10.1185/03007999909116497 – volume: 42 start-page: 377 issue: 2 year: 2009 ident: 1502_CR22 publication-title: J Biomed Inform doi: 10.1016/j.jbi.2008.08.010 – volume: 34 start-page: 126 issue: 2 year: 2014 ident: 1502_CR24 publication-title: Cephalalgia. doi: 10.1177/0333102413500726 – volume: 55 start-page: 1511 issue: 10 year: 2000 ident: 1502_CR27 publication-title: Neurology. doi: 10.1212/WNL.55.10.1511 – volume: 322 start-page: 1887 issue: 19 year: 2019 ident: 1502_CR38 publication-title: JAMA. doi: 10.1001/jama.2019.16711 – volume: 49 start-page: 1258 issue: 9 year: 2009 ident: 1502_CR18 publication-title: Headache. doi: 10.1111/j.1526-4610.2009.01523.x – volume: 38 start-page: 288 issue: 4 year: 1998 ident: 1502_CR11 publication-title: Headache. doi: 10.1046/j.1526-4610.1998.3804288.x – volume: 43 start-page: 376 issue: 4 year: 2003 ident: 1502_CR16 publication-title: Headache. doi: 10.1046/j.1526-4610.2003.03073.x – volume: 142 start-page: 1894 issue: 7 year: 2019 ident: 1502_CR37 publication-title: Brain. doi: 10.1093/brain/awz134 – volume: 20 start-page: 57 issue: 1 year: 2019 ident: 1502_CR7 publication-title: J Headache Pain. doi: 10.1186/s10194-018-0899-2 – volume: 12 start-page: 5 issue: 1 year: 2011 ident: 1502_CR19 publication-title: J Headache Pain doi: 10.1007/s10194-010-0258-4 – volume: 134 start-page: 178 year: 2021 ident: 1502_CR20 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2021.03.001 – volume: 18 start-page: 273 issue: 5 year: 1998 ident: 1502_CR25 publication-title: Cephalalgia. doi: 10.1046/j.1468-2982.1998.1805273.x – volume: 59 start-page: 1002 issue: 7 year: 2019 ident: 1502_CR29 publication-title: Headache doi: 10.1111/head.13530 – volume: 58 start-page: 986 issue: 7 year: 2018 ident: 1502_CR36 publication-title: Headache doi: 10.1111/head.13327 – volume: 26 start-page: 98 issue: 2 year: 2006 ident: 1502_CR13 publication-title: Cephalalgia. doi: 10.1111/j.1468-2982.2005.01010.x – volume: 58 start-page: 247 issue: 4 year: 2002 ident: 1502_CR15 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-002-0461-6 – ident: 1502_CR33 doi: 10.3390/jcm10071429
SSID	ssj0020385
Score	2.5044248
SecondaryResourceType	review_article
Snippet	Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The... BackgroundTriptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The... Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim... Background. Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The... Abstract Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for...
SourceID	doaj pubmedcentral hal proquest crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher
StartPage	133
SubjectTerms	Attack Clinical medicine Consensus Consensus Article Ditan Drug resistance Gepant Headache Headaches Internal Medicine Life Sciences Literature reviews Medication Medicine Medicine & Public Health Migraine Neurobiology Neurology Neurons and Cognition Pain management Pain Medicine Patients Pharmaceutical sciences Triptan Well being
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07j9QwELbQFYgG8RSBAxlEAYKIxPEr5YFuFSGg4qTrLD-5FZBFbJbiOv45M06yXE4CGrpd2xtHM2N7ZufzN4Q8hSMiONGKUjtbldxVvnQi6TKCi1RHyYNwGW3xQXYn_O2pOL1Q6gsxYSM98Ci4V4lFcFK8ahNXXDLnlG1YFfEqdFs3NuLuC5_mYGoKtTDflcuqsLZkjWzn6zJa4qW5GulwGUISBOwH54sjKTP3w0FzhrjIC07nZcjkpbxpPo5WN8j1yY-kR-P73yRXYn-LXH0_Zcpvk5_z3-y0Ay0iazNdIW9EVgR9dtytnlOPSOp-u9tSaAJHkIaY1n3GcNFNoiPUA3ZDukejY7OlX9efsLBEpHYYrP9MbR-wY8D9ByZMdo1Y9zvkZHX88U1XTuUWSi90NZQxgjeWmjZBBNUm-BaEkE5yHZT2likbZVJRsGQrxwNsBixoz5WEl-cyuLq5Sw76TR_vEeoDdLrgqgThCmdOe197kZhCTuRWh4LUs8SNn7jIsSTGF5NjEi3NqCUDWjJZS-a8IC_2v_k2MnH8dfRrVOR-JLJo5wawLTPZlvmXbRXkCZjB4hnd0TuDbRWEtQLk9aMuyOFsJWZa_1vDFEbK4JuKgjzed8PKxXSM7eNmN47BR0hdELWwrsWMy55-fZY5wFuBGc6mIC9nO_w9-Z-lcv9_SOUBucZw9WRYzyE5GL7v4kPwzAb3KC_CX3S_Mow priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLxVMECjKIAwgiEid-5IQK6ipCwIlKe7P8bFdAtu1mOfTGP2fGSXbZSvQY24kjz3gens8zhLwCFeEtb3iurCny2hYutzyqPICJVAZRe24T2uKbaI_rz3M-Hw_cViOscpKJSVD7pcMz8vdMou8B2p5_ODvPsWoURlfHEho3yS1MXYaQLjnfOlwY9UrFVViTs0o006UZJfDqXIlJcRkCEzhIhcsdxZTy94O6OUV05D-m51Xg5JXoaVJKs7tkf7Qm6eFA_nvkRujuk9tfx3j5A_JnOmynLdASczfTGWaPSOSgr4_a2RvqEE_drdYrCk1gDlIf4qJLSC66jHQAfIBMpBtMOjYb-mtxguUlAjV9b9wPajqPHT1KIZgwmgUi3h-S49nR909tPhZdyB1XRZ-HADZZrJoIflQT4clzLqyolZfKGSZNEFEGzqIpbO1BJDCvXC0F_HwtvC2rR2SvW3bhMaHOQ6f1tojgtNTMKudKxyOTmBm5UT4j5bTi2o0ZybEwxk-dPBMl9EAlDVTSiUr6MiNvN--cDfk4rh39EQm5GYm5tFPD8uJEj1tTRxbADHayibWsBbNWmooVAS_bN2VlQkZeAhvsfKM9_KKxrQDnlsN6_S4zcjBxiR6lwEpveTYjLzbdsH8xKGO6sFwPY_ATQmVE7nDXzoy7Pd3iNGUCbzjGOauMvJv4cDv5_1flyfX_-pTcYbgvEmzngOz1F-vwDCyv3j5P2-svv7Yqtw priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C24 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgL4ikCBRnEAQSREsevHEvV1QoBJyr1ZvnZrgpZ1M1y6I1_zoyTLKQCJI5re-2VZ8ae2fnmMyEv4YoITrSi1M5WJXeVL51IuozgItVR8iBcRlt8kstj_v5EnIxFYZsJ7T6lJPNJnc1aSyx2q5HGliGUQIAdX14nNwTE7qjXh1jjMIZZmOvKT6qwtmSNbKdSmT_OMbuOMms_XDJniIn8zeG8Cpe8kjPNV9HiDrk9-pD0YBD6XXItdvfIzY9jlvw--TH9xU6XIEFkbKYL5IzIQqCvjpaL19QjirrbbDcUmsAJpCGmVZfxW3Sd6ADzgJOQ7pDo2Gzp19UpPioRqe1768-p7QJ29Hj2wILJrhDn_oAcL44-Hy7L8amF0gtd9WWM4Imlpk0QPbUJPgUhpJNcB6W9ZcpGmVQULNnK8QAHAQvacyXhx3MZXN08JHvduouPCPUBOl1wVYJQhTOnva-9SEwhH3KrQ0HqaceNH3nI8TmMLybHI1qaQUoGpGSylMxlQd7svvNtYOH45-h3KMjdSGTQzg3ri1MzGqRJLILz61WbuOKSOadsw6qIJfZt3dhYkBegBrM5lgcfDLZVENIK2K_vdUH2Jy0xo-1vDFMYJYNfKgryfNcNVoupGNvF9XYYg1NIXRA1067ZivOebnWW-b9bgdnNpiBvJz38tfjfd-Xx_w1_Qm4xtJMM3tkne_3FNj4F_6t3z7K5_QRLGCfl priority: 102 providerName: Springer Nature
Title	European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
URI	https://link.springer.com/article/10.1186/s10194-022-01502-z https://www.proquest.com/docview/2724075615 https://www.proquest.com/docview/2724583568 https://hal.umontpellier.fr/hal-04485835 https://pubmed.ncbi.nlm.nih.gov/PMC9555163 https://doaj.org/article/f2e139c79f47462bb7a320e0480913ae
Volume	23
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf2ISFeEJ8iMCqDeABBUOL4I3lAqKtaKsQmhKjUt8iO7a3aSKFNEeyN_5w7Nyl0GogXS7EdO_Ld2Xe5n-8IeQpHhDWiEHFudBJzk1SxET6PHahIqZPcChPQFsdyPOHvpmK6Q7p0R-0CLq807TCf1GRx_ur71x9vQOBfB4HPJV6DSzHALUOQgQAJv9gl-3AyKRTUI77xKjD0goVkK6yIWaZUd4nmyjG2DqoQzx-On1NES_6hil4GUl7ypoZDanST3Gi1S9pfs8MtsuPq2-TaUes_v0N-dj_f6Rhoi7Gc6QijSQTy0GfD8eg5rRBfXS9XSwpVoB5S6_ysDsguOvd0DQCBPZJuMOpYrenn2Qmmm3BUN42uzqiuLTY0uCvBhF7PEAF_l0xGw0-DcdwmYYgrkSdN7BzoaD4rPNhVhYcnK4Q0kudW5ZVmSjvplRPM68RwC1sEs3nFlYSP59KaNLtH9up57e4TWlloNNYkHowYzkxeVWklPFMYKbnIbUTSbsXLqo1QjokyzstgqeSyXFOpBCqVgUrlRURebN75so7P8c_eh0jITU-MrR0q5ouTshXV0jMHanGlCs8Vl8wYpTOWOLx8X6SZdhF5AmywNca4_77EugSMXQHr9S2NyEHHJWXH1CVTaD-Dxioi8njTDPKMThpdu_lq3QeHkHlE1BZ3bc243VLPTkNk8EKg3zOLyMuOD39P_vdVefAfH_OQXGcoHAHLc0D2msXKPQJ1rDE9ssuTt1CqqeqR_cPh8YeP8DRgHEs56IXfHL0giVBOWP8X9rg3AA
linkProvider	Scholars Portal
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiKcIFDAIJBBEJE7sJAeEWthVSrcVQq3Um_GzXQHZ0s2C6I0_xG9kJo8tW4neeozt2JFnPI_M5xlCnoKKsJoXPMy1isJURybU3OehAxMpdiK1XDdoix1R7qUf9vn-CvnT34VBWGUvExtBbacG_5G_Zhn6HqDt-duj7yFWjcLoal9Co2WLLffrJ7hsszeb74G-zxgbDXfflWFXVSA0PI_q0DkwOnxSeHAUCg9PlnOhRZrbLDeKZcoJnznOvIp0aoHnmc1NmglnXSqsjhOY9xJZTRNwZQZkdWO48_HTwsXDOFtTzoUVIUtE0V_TyQVe1osxDS9DKAQHOXSypAqbigGg4A4Rj_mPsXsWqnkmXtuowdF1cq2zX-l6y3A3yIqrbpLL212E_hb53f_epyVwD2aLpiPMV9EwAH0-LEcvqEEEdzWbzyg0gQFKrfOTqsGO0amnLcQEpDBdoOCxWdFvkwMsaOGoqmtlvlBVWeyoUe7Bgl5NEGN_m-xdCEHukEE1rdxdQo2FTm115MFNSpnOjYkN9yzDXMxFbgMS9zsuTZcDHUtxfJWNL5QL2VJJApVkQyV5EpCXi3eO2gwg547eQEIuRmL27qZhenwgO2EgPXNgeJus8GmWCqZ1phIWObzeX8SJcgF5AmywNEe5PpbYFoE7zWG_fsQBWeu5RHZyZyZPT0lAHi-6QWJgGEhVbjpvx-AUIg9ItsRdSysu91STwyb3eMExspoE5FXPh6eL_39X7p3_rY_IlXJ3eyzHmztb98lVhmekAQ2tkUF9PHcPwO6r9cPusFHy-aLP919wVGoW
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouiKcIFDAIJBBETZzYTg4IFdrVlpaKA5X2lvrZroBs6WZB9Mbf4tcx4yS7bCV66zG2Y0eeh2cyn2cIeQZHhNW85HGhVRLnOjGx5r6IHZhIqRO55TqgLfbF8CD_MOKjFfKnvwuDsMpeJwZFbScG_5FvMIm-B5z2fMN3sIhPW4O3J99jrCCFkda-nEbLIrvu109w36ZvdraA1s8ZG2x_fj-MuwoDseFF0sTOgQHis9KD01B6eLKcCy3ywsrCKCaVE146zrxKdG6B_5ktTC6Fsy4XVqcZzHuFXJUZT1HG5Gjh7GHELRR2YWXMMlH2F3YKgdf2UkzIyxAUwUEjnS0diqF2ABx1x4jM_MfsPQ_aPBe5DQfi4Aa53lmydLNlvZtkxdW3yNrHLlZ_m_zuf_TTIfAR5o2mA8xcEViBvtgeDl5Sg1juejqbUmgCU5Ra58d1QJHRiact2AT0MZ3j4bFZ0W_jIyxt4ahqGmW-UFVb7GhQA8KCXo0RbX-HHFwKOe6S1XpSu3uEGgud2urEg8OUM10YkxrumcSszGVhI5L2O16ZLhs6FuX4WgWvqBBVS6UKqFQFKlVnEXk1f-ekzQVy4eh3SMj5SMzjHRomp0dVpxYqzxyY4EaWPpe5YFpLlbHE4UX_Ms2Ui8hTYIOlOYabexW2JeBYc9ivH2lE1nsuqToNNK0W8hKRJ_Nu0B0YEFK1m8zaMTiFKCIil7hracXlnnp8HLKQlxxjrFlEXvd8uFj8_7ty_-JvfUzWQKqrvZ393QfkGkMRCeihdbLanM7cQzAAG_0oSBolh5ct2n8BQwRs5g
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=European+Headache+Federation+%28EHF%29+consensus+on+the+definition+of+effective+treatment+of+a+migraine+attack+and+of+triptan+failure&rft.jtitle=Journal+of+headache+and+pain&rft.au=Sacco%2C+Simona&rft.au=Lampl%2C+Christian&rft.au=Amin%2C+Faisal+Mohammad&rft.au=Braschinsky%2C+Mark&rft.date=2022-10-12&rft.issn=1129-2377&rft.eissn=1129-2377&rft.volume=23&rft.issue=1&rft.spage=133&rft_id=info:doi/10.1186%2Fs10194-022-01502-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1129-2369&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1129-2369&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1129-2369&client=summon